Departement
Klinische Forschung
Achtung: Diese Seite kann nur von Administratoren besucht werden, da Sie nicht freigeschalten wurde.
Zurück
Publications Läubli Heinz

Fibroblast activation protein-targeted-4-1BB ligand agonist amplifies effector functions of intratumoral T cells in human cancer.

Trüb M; Uhlenbrock F; Claus C; Herzig P; Thelen M; Karanikas V; Bacac M; Amann M; Albrecht R; Ferrara-Koller C; Thommen D; Rothschield S; Savic Prince S; Mertz KD; Cathomas G; Rosenberg R; Heinzelmann-Schwarz V; Wiese M; Lardinois D; Umana P; Klein C; Laubli H; Kashyap AS; Zippelius A. Journal for ImmunoTherapy of Cancer. 2020.

Hyperglycemia Enhances Cancer Immune Evasion by Inducing Alternative Macrophage Polarization through Increased O-GlcNAcylation.

Rodrigues Mantuano N; Stanczak MA; Oliveira IA; Kirchhammer N; Filardy AA; Monaco G; Santos RC; Fonseca AC; Fontes M; Bastos CS Jr; Dias WB; Zippelius A; Todeschini AR; Läubli H. Cancer Immunology Research. 2020.

PD-1<sup>+</sup> natural killer cells in human non-small cell lung cancer can be activated by PD-1/PD-L1 blockade.

Trefny MP; Kaiser M; Stanczak MA; Herzig P; Savic S; Wiese M; Lardinois D; Läubli H; Uhlenbrock F; Zippelius A. Cancer immunology, immunotherapy : CII. 2020.

Response to Comment on Trinh et al. Successful Treatment of Immune Checkpoint Inhibitor-Induced Diabetes With Infliximab. Diabetes Care 2019;42:e153-e154.

Trinh B; Donath MY; Läubli H. . 2020.

Sialic acid-binding immunoglobulin-like lectins (Siglecs) detect self-associated molecular patterns to regulate immune responses.

Läubli H; Varki A. . 2020.

Tumor-associated carbohydrates and immunomodulatory lectins as targets for cancer immunotherapy.

Rodrigues Mantuano N; Natoli M; Zippelius A; Läubli H. Journal for ImmunoTherapy of Cancer. 2020.

Tumor mutational burden assessed by targeted NGS predicts clinical benefit from immune checkpoint inhibitors in non-small cell lung cancer.

Alborelli I; Leonards K; Rothschild SI; Leuenberger LP; Savic Prince S; Mertz KD; Poechtrager S; Buess M; Zippelius A; Läubli H; Haegele J; Tolnay M; Bubendorf L; Quagliata L; Jermann P. The Journal of pathology. 2020.

Altered Cell Adhesion and Glycosylation Promote Cancer Immune Suppression and Metastasis.

Läubli H; Borsig L. Frontiers in Immunology. 2019.

Association of Checkpoint Inhibitor-Induced Toxic Effects With Shared Cancer and Tissue Antigens in Non-Small Cell Lung Cancer.

Berner F; Bomze D; Diem S; Ali OH; Fässler M; Ring S; Niederer R; Ackermann CJ; Baumgaertner P; Pikor N; Cruz CG; van de Veen W; Akdis M; Nikolaev S; Läubli H; Zippelius A; Hartmann F; Cheng HW; Hönger G; Recher M; Goldman J; Cozzio A; Früh M; Neefjes J; Driessen C; Ludewig B; Hegazy AN; Jochum W; Speiser DE; Flatz L. JAMA Oncology. 2019.

A Variant of a Killer Cell Immunoglobulin-like Receptor Is Associated with Resistance to PD-1 Blockade in Lung Cancer.

Trefny MP; Rothschild SI; Uhlenbrock F; Rieder D; Kasenda B; Stanczak MA; Berner F; Kashyap AS; Kaiser M; Herzig P; Poechtrager S; Thommen DS; Geier F; Savic S; Jermann P; Alborelli I; Schaub S; Stenner F; Früh M; Trajanoski Z; Flatz L; Mertz KD; Zippelius A; Läubli H. Clinical cancer research : an official journal of the American Association for Cancer Research. 2019.

B cells sustain inflammation and predict response to immune checkpoint blockade in human melanoma.

Griss J; Bauer W; Wagner C; Simon M; Chen M; Grabmeier-Pfistershammer K; Maurer-Granofszky M; Roka F; Penz T; Bock C; Zhang G; Herlyn M; Glatz K; Läubli H; Mertz KD; Petzelbauer P; Wiesner T; Hartl M; Pickl WF; Somasundaram R; Steinberger P; Wagner SN. Nature Communications. 2019.

GEF-H1 Signaling upon Microtubule Destabilization Is Required for Dendritic Cell Activation and Specific Anti-tumor Responses.

Kashyap AS; Fernandez-Rodriguez L; Zhao Y; Monaco G; Trefny MP; Yoshida N; Martin K; Sharma A; Olieric N; Shah P; Stanczak M; Kirchhammer N; Park SM; Wieckowski S; Laubli H; Zagani R; Kasenda B; Steinmetz MO; Reinecker HC; Zippelius A. Cell Reports. 2019.

Immune tumor board: integral part in the multidisciplinary management of cancer patients treated with cancer immunotherapy.

Läubli H; Dirnhofer S; Zippelius A. Virchows Archiv. 2019.

Inflammation-induced hypoparathyroidism triggered by combination immune checkpoint blockade for melanoma.

Trinh B; Sanchez GO; Herzig P; Läubli H. Journal for ImmunoTherapy of Cancer. 2019.

Publisher Correction: Uncoupling protein 2 reprograms the tumor microenvironment to support the anti-tumor immune cycle.

Cheng WC; Tsui YC; Ragusa S; Koelzer VH; Mina M; Franco F; Läubli H; Tschumi B; Speiser D; Romero P; Zippelius A; Petrova TV; Mertz K; Ciriello G; Ho PC. . 2019.

Siglec-9 Regulates an Effector Memory CD8<sup>+</sup> T-cell Subset That Congregates in the Melanoma Tumor Microenvironment.

Haas Q; Boligan KF; Jandus C; Schneider C; Simillion C; Stanczak MA; Haubitz M; Seyed Jafari SM; Zippelius A; Baerlocher GM; Läubli H; Hunger RE; Romero P; Simon HU; von Gunten S. Cancer Immunology Research. 2019.

Successful Treatment of Immune Checkpoint Inhibitor-Induced Diabetes With Infliximab.

Trinh B; Donath MY; Läubli H. DIABETES CARE. 2019.

Therapeutic Targeting of Golgi Phosphoprotein 2 (GOLPH2) with Armed Antibodies: A Preclinical Study of Anti-GOLPH2 Antibody Drug Conjugates in Lung and Colorectal Cancer Models of Patient Derived Xenografts (PDX).

Liewen H; Markuly N; Läubli H; Liu Y; Matter MS; Liewen N; Renner C; Zippelius A; Stenner F. Targeted Oncology. 2019.

The sialoglycan-Siglec glyco-immune checkpoint - a target for improving innate and adaptive anti-cancer immunity.

Bärenwaldt A; Läubli H. EXPERT OPINION ON THERAPEUTIC TARGETS. 2019.

Toxicity associated with PD-1 blockade after allogeneic haematopoietic cell transplantation.

Ortega Sanchez G; Stenner F; Dirnhofer S; Passweg J; Gerull S; Halter JP; Zippelius A; Läubli H. Swiss medical weekly. 2019.

Uncoupling protein 2 reprograms the tumor microenvironment to support the anti-tumor immune cycle.

Cheng WC; Tsui YC; Ragusa S; Koelzer VH; Mina M; Franco F; Läubli H; Tschumi B; Speiser D; Romero P; Zippelius A; Petrova TV; Mertz K; Ciriello G; Ho PC. NATURE IMMUNOLOGY. 2019.

Cancer Immunotherapy.

Pearce OMT; Läubli H. GLYCOBIOLOGY. 2018.

Immunotherapy in head and neck cancer - scientific rationale, current treatment options and future directions.

Rothschild U; Muller L; Lechner A; Schlösser HA; Beutner D; Läubli H; Zippelius A; Rothschild SI. Swiss medical weekly. 2018.

Influenza vaccination of cancer patients during PD-1 blockade induces serological protection but may raise the risk for immune-related adverse events.

Läubli H; Balmelli C; Kaufmann L; Stanczak M; Syedbasha M; Vogt D; Hertig A; Müller B; Gautschi O; Stenner F; Zippelius A; Egli A; Rothschild SI. Journal for ImmunoTherapy of Cancer. 2018.

Self-associated molecular patterns mediate cancer immune evasion by engaging Siglecs on T cells.

Stanczak MA; Siddiqui SS; Trefny MP; Thommen DS; Boligan KF; von Gunten S; Tzankov A; Tietze L; Lardinois D; Heinzelmann-Schwarz V; von Bergwelt-Baildon M; Zhang W; Lenz HJ; Han Y; Amos CI; Syedbasha M; Egli A; Stenner F; Speiser DE; Varki A; Zippelius A; Läubli H. The Journal of clinical investigation. 2018.

Targeting sialic acid-Siglec interactions to reverse immune suppression in cancer.

Adams OJ; Stanczak MA; von Gunten S; Läubli H. GLYCOBIOLOGY. 2018.

The multi-receptor inhibitor axitinib reverses tumor-induced immunosuppression and potentiates treatment with immune-modulatory antibodies in preclinical murine models.

Läubli H; Müller P; D'Amico L; Buchi M; Kashyap AS; Zippelius A. Cancer immunology, immunotherapy : CII. 2018.

The T cell repertoire in tumors overlaps with pulmonary inflammatory lesions in patients treated with checkpoint inhibitors.

Läubli H; Koelzer VH; Matter MS; Herzig P; Dolder Schlienger B; Wiese MN; Lardinois D; Mertz KD; Zippelius A. Oncoimmunology. 2018.

Treatment of mycophenolate-resistant immune-related organizing pneumonia with infliximab.

Ortega Sanchez G; Jahn K; Savic S; Zippelius A; Läubli H. Journal for ImmunoTherapy of Cancer. 2018.

Cerebral vasculitis mimicking intracranial metastatic progression of lung cancer during PD-1 blockade.

Läubli H; Hench J; Stanczak M; Heijnen I; Papachristofilou A; Frank S; Zippelius A; Stenner-Liewen F. Journal for ImmunoTherapy of Cancer. 2017.

Antimetastatic Properties of Low Molecular Weight Heparin.

Läubli H; Varki A; Borsig L. JOURNAL OF CLINICAL ONCOLOGY. 2016.

Sialic acids in cancer biology and immunity.

Pearce OM; Läubli H. GLYCOBIOLOGY. 2016.

A red meat-derived glycan promotes inflammation and cancer progression.

Samraj AN; Pearce OM; Läubli H; Crittenden AN; Bergfeld AK; Banda K; Gregg CJ; Bingman AE; Secrest P; Diaz SL; Varki NM; Varki A. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. 2015.

Reply to Mackenzie: A comparison of Neu5Gc and α-gal xenoantigens.

Pearce OM; Samraj AN; Läubli H; Varki NM; Varki A. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. 2015.

Siglec receptors impact mammalian lifespan by modulating oxidative stress.

Schwarz F; Pearce OM; Wang X; Samraj AN; Läubli H; Garcia JO; Lin H; Fu X; Garcia-Bingman A; Secrest P; Romanoski CE; Heyser C; Glass CK; Hazen SL; Varki N; Varki A; Gagneux P. Elife. 2015.

Engagement of myelomonocytic Siglecs by tumor-associated ligands modulates the innate immune response to cancer.

Läubli H; Pearce OM; Schwarz F; Siddiqui SS; Deng L; Stanczak MA; Deng L; Verhagen A; Secrest P; Lusk C; Schwartz AG; Varki NM; Bui JD; Varki A. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. 2014.

Hormesis in cancer immunology: Does the quantity of an immune reactant matter?

Pearce OM; Läubli H; Bui J; Varki A. Oncoimmunology. 2014.

Inverse hormesis of cancer growth mediated by narrow ranges of tumor-directed antibodies.

Pearce OM; Läubli H; Verhagen A; Secrest P; Zhang J; Varki NM; Crocker PR; Bui JD; Varki A. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. 2014.

Involvement of a non-human sialic Acid in human cancer.

Samraj AN; Läubli H; Varki N; Varki A. Frontiers in Oncology. 2014.

Lectin galactoside-binding soluble 3 binding protein (LGALS3BP) is a tumor-associated immunomodulatory ligand for CD33-related Siglecs.

Läubli H; Alisson-Silva F; Stanczak MA; Siddiqui SS; Deng L; Verhagen A; Varki N; Varki A. JOURNAL OF BIOLOGICAL CHEMISTRY. 2014.

Selectins as mediators of lung metastasis.

Läubli H; Borsig L. Cancer Microenvironment. 2010.

Selectins promote tumor metastasis.

Läubli H; Borsig L. SEMINARS IN CANCER BIOLOGY. 2010.

Heparins attenuate cancer metastasis: are selectins the link?

Laubli H; Borsig L. CANCER INVESTIGATION. 2009.

Selectin-mediated activation of endothelial cells induces expression of CCL5 and promotes metastasis through recruitment of monocytes.

Läubli H; Spanaus KS; Borsig L. Blood. 2009.

L-selectin facilitation of metastasis involves temporal induction of Fut7-dependent ligands at sites of tumor cell arrest.

Läubli H; Stevenson JL; Varki A; Varki NM; Borsig L. Cancer research. 2006.